Name Address City

Zip

State --- AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY

Phone Diagnosis Select... Bladder Cancer Heart Attack Congestive Heart Failure Other Unknown Email Comments

Actos Lawyer

The FDA issued a consumer update in June 2011 stating that the use of Actos for more than a year may increase the risk of bladder cancer. Actos is prescribed for blood sugar control issues associated with type 2 diabetes. If you were prescribed Actos to treat diabetes at any point before June 2011, you may be eligible to file a lawsuit against the medication's distributing company, Takeda Pharmaceuticals. An Actos lawyer who is knowledgeable about the side effects of the drug and the legal issues involved in light of the FDA's recent findings can help you receive the compensation you deserve.

Results from the FDA's five-year review of a continuing pioglitazone study show a higher risk of bladder cancer in patients who use Actos for longer periods of time at higher doses. A ten-year study involving 193,099 patients showed that those who had taken Actos for longer than a year were 40% more likely to develop bladder cancer. As a result of the FDA's findings, certain European countries have suspended the sale of Actos, including Germany and France.

The update also explained that from now on a warning describing the possible link between Actos and bladder cancer will be included on the label and patient medication guide of any medicine containing pioglitazone, the active ingredient in Actos. Prior to the FDA's announcement, no information about the potential bladder cancer risk of Actos side effects was distributed in any form with the medication.

You may want to consider filing an Actos lawsuit if you took the medication prior to June 2011. Since Takeda Pharmaceuticals distributed Actos to individuals without properly researching the negative effects pioglitazone might have on the human body and notifying recipients, the company may be obligated to make compensation.

Actos serves two main purposes for patients with type 2 diabetes: helping them use insulin more effectively and stopping their liver from producing excess sugar. While warnings directed toward patients with heart failure were distributed on the label and in the patient medication guide included with Actos, there was no mention of an increased risk of bladder cancer. Due to this major medical oversight, anyone who was prescribed Actos to treat diabetes before the FDA made its announcement may be eligible for significant compensation from Takeda Pharmaceuticals.